Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases

Maze Therapeutics CEO Jason Coloma details his transition from academic research to biotech leadership, emphasizing the power of human genetics in drug discovery. The company leverages large-scale datasets, such as the UK Biobank, to identify genetic variants that protect against or cause complex conditions like chronic kidney disease. Coloma recounts the company's resilience through lean financing periods, including navigating a challenging antitrust intervention regarding a partnership for a Pompeii disease program. By focusing on small molecule therapies and fostering a culture of adaptability, Maze aims to develop disease-modifying treatments for patients with limited options. The conversation highlights the evolving regulatory environment for kidney disease, where data-driven biomarker endpoints are increasingly facilitating clinical development, and underscores the importance of building an enduring, independent company that integrates high-level science with commercial execution.